Atrium Therapeutics, Inc.

Today, RNA trades at 8.72 USD.

For broader market analysis, dive into the technicals on the Atrium Therapeutics, Inc. stock price chart and read the latest RNA news:
– Atrium Therapeutics to Present ATR 1072 Nonclinical PRKAG2 Data at AHA Sessions
– Atrium Therapeutics Is Maintained at Buy by HC Wainwright & Co.
– HC Wainwright & Co. maintains Buy rating on Atrium Therapeutics, $20 price target

Markets don't sleep, here's what's going on with RNA at the moment:
– Atrium Therapeutics to Present ATR 1072 Nonclinical PRKAG2 Data at AHA Sessions
– Atrium Therapeutics Is Maintained at Buy by HC Wainwright & Co.
– HC Wainwright & Co. maintains Buy rating on Atrium Therapeutics, $20 price target

See more updates in real-time with our News Flow.

Atrium Therapeutics, Inc. is scheduled to release its next earnings report on Dec 2, 2026.

Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release

How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts

RNA stock is 3.79% volatile and has beta coefficient of 1.43.

What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable

Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like RNA are typically less volatile than smaller companies

Track every detail on Atrium Therapeutics, Inc. stock chart and check out the list of the most volatile stocks — is Atrium Therapeutics, Inc. there?

To understand the RNA stock performance, it's worth checking price changes for various periods to get the full picture:
– 1 day — +3.39%
– 1 week — +4.27%
– 1 month — +4.01%

RNA all-time low was 7.49 USD (Oct 19, 2026), and its highest price is 16.77 USD (Mar 5, 2026). Find more dynamics in the Stock Heatmap and on the Atrium Therapeutics, Inc. stock chart.

Atrium Therapeutics, Inc. market capitalization is ‪190.46 M‬, representing the total value of all its outstanding shares (price × shares outstanding).

What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements

What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Atrium Therapeutics, Inc. stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Atrium Therapeutics, Inc. stacks up against other companies

The safest way to buy Atrium Therapeutics, Inc. stocks is through a reliable broker. Create an account, fund it, and place a buy order.

You can trade RNA directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart

Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.

Atrium Therapeutics, Inc. stock ticker depends on the exchange where it’s listed. On the NASDAQ, its primary exchange, Atrium Therapeutics, Inc. stocks trade under the symbol RNA.

About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners

Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion

Learn how to find your desired assets in our Symbol Search.

RNA earnings for the last quarter are −1.18 USD per share, whereas the estimation was −1.42 USD, resulting in a 16.75% surprise. The estimated earnings for the next quarter are −0.81 USD per share.

How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple quarters, not just one

Follow other essential metrics in Atrium Therapeutics, Inc. financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk

Atrium Therapeutics, Inc. revenue for the last quarter amounts to ‪3.00 M‬ USD despite the estimated figure of ‪666.67 K‬ USD. In the next quarter revenue is expected to reach ‪15.00 M‬ USD.

How to read this data:
– Compare actual vs estimates: Revenue beats or misses can move the stock
– Watch market reaction: Price response shows how investors interpret results
– Look at growth: Compare with previous quarters and year-over-year data
– Track trends: One quarter matters less than consistent performance

Follow other essential metrics in Atrium Therapeutics, Inc. financials:
– Earnings (EPS): Profitability per share
– Margins (gross, operating): Efficiency and cost control
– Free cash flow: Cash available after expenses

Yes, you can track Atrium Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.

Use our Earnings Calendar to never miss important releases and spot opportunities early.

RNA net income for the last quarter is ‪−20.19 M‬ USD, while the quarter before that showed ‪−16.63 M‬ USD of net income which accounts for −21.36% change.

How to read this data:
– Track changes: Compare net income across quarters to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one quarter: Consistency matters more than a single result

Follow other essential metrics in Atrium Therapeutics, Inc. financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control

No, Atrium Therapeutics, Inc. does not currently pay dividends to its shareholders.

Instead of distributing profits as cash payments, the company may choose to reinvest earnings back into the business — for example, in growth, innovation, acquisitions, or debt reduction.

What to consider instead:
– Earnings growth: Is the company increasing profitability over time?
– Revenue expansion: Is the business scaling its operations?
– Free cash flow: Does it generate enough cash to potentially support future dividends?
– Share buybacks: Some companies return capital through repurchasing shares instead of dividends

RNA reached its all-time high of 16.77 USD on Mar 5, 2026. Its all-time low was 7.49 USD and was reached on Oct 19, 2026.

Explore the Atrium Therapeutics, Inc. stock price chart to see more price history, and discover companies reaching new all-time highs and lows.